Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roger Stupp MD
Roger Stupp MD Advisory Board
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · April 24, 2022

Assessment of Clinical Response After Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

JAMA Oncology
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial
JAMA Oncol 2022 Apr 07;[EPub Ahead of Print], DM Halperin, S Liu, A Dasari, D Fogelman, P Bhosale, A Mahvash, JS Estrella, L Rubin, AC Morani, M Knafl, TA Overeem, SC Fu, LM Solis, E Parra Cuentas, A Verma, HL Chen, S Gite, P Subashchandrabose, S Dervin, K Schulze, WC Darbonne, C Yun, II Wistuba, PA Futreal, SE Woodman, JC Yao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated